Curasight announced an accelerated strategy for its theranostics platforn this morning, with the purpose of advancing forward in several cancer indications. The strategy involves a coming ph I/IIa basket trial including five different cancer indications, where both uTRACE and uTREAT will be combined in the study. First patient expected to be dosed in the beginning of 2025 with efficacy data in 2025.
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.